Short Interest in Aptorum Group Limited (NASDAQ:APM) Decreases By 30.0%

Aptorum Group Limited (NASDAQ:APM) was the target of a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 4,200 shares, a decrease of 30.0% from the August 31st total of 6,000 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 13,700 shares, the short-interest ratio is currently 0.3 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptorum Group stock. Murchinson Ltd. bought a new position in shares of Aptorum Group Limited (NASDAQ:APM) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned approximately 0.27% of Aptorum Group as of its most recent SEC filing. 3.80% of the stock is currently owned by hedge funds and other institutional investors.

Aptorum Group Stock Performance

Shares of NASDAQ:APM traded down $0.02 on Friday, reaching $1.85. 15,262 shares of the company’s stock were exchanged, compared to its average volume of 830,728. The company has a fifty day moving average of $2.92 and a 200-day moving average of $4.73. Aptorum Group has a twelve month low of $1.35 and a twelve month high of $17.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.18 and a current ratio of 1.18.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.